AA-METOPROLOL SR TABLET (EXTENDED-RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

METOPROLOL TARTRATE

제공처:

AA PHARMA INC

ATC 코드:

C07AB02

INN (국제 이름):

METOPROLOL

복용량:

200MG

약제 형태:

TABLET (EXTENDED-RELEASE)

구성:

METOPROLOL TARTRATE 200MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

BETA-ADRENERGIC BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0111923001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2022-10-13

제품 특성 요약

_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AA-METOPROLOL SR
Metoprolol Tartrate Prolonged-release Tablets
Prolonged-release tablets, 100 mg and 200 mg, oral
House Standard
Beta-Adrenergic Receptor Blocking Agent
AA Pharma Inc.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Revision:
October 12, 2022
Submission Control Number: 262717
_AA-METOPROLOL SR (Metoprolol Tartrate Tablets) _
_ _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
....................................................................................................................4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS.......................................................................................................5
4
DOSAGE AND ADMINISTRATION
.......................................................................................5
4.1
Dosing Considerations
................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 6
4.4
Administration............................................................................................................
8
4.5
Missed Dose
.